Piramal Pharma (NSE:PPLPHARMA) EBIT: ₹1,647 Mil (TTM As of Mar. 2026)


NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
53 GF Score
Price ₹167.69
GF Value ₹175.28
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Piramal Pharma EBIT?

Piramal Pharma NSE:PPLPHARMA -2.75% 53 EBIT is ₹1,647 Mil as of Mar. 2026. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 53/100 and a GF Value™ of ₹175.28 (Fairly Valued). The stock has 3 warning signs investors should review.

Piramal Pharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹1,260 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,647 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Piramal Pharma's annualized ROC % for the quarter that ended in Mar. 2026 was 0.00%. Piramal Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 6.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Piramal Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 0.62%.

Piramal Pharma  (NSE:PPLPHARMA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Piramal Pharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=9685.2 * ( 1 - 100% )/( (0 + 140545)/ 1 )
=0/140545
=0.00 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=179650.4 - 24896.6 - ( 14208.8 - max(0, 47582.8 - 71916.6+14208.8))
=140545

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Piramal Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=5039.6/( ( (0 + max(0, 0)) + (56418.5 + max(22516.9, 0)) )/ 1 )
=5039.6/( ( 0 + 78935.4 )/ 1 )
=5039.6/78935.4
=6.38 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(21576.7 + 30644.4 + 5486.7) - (24896.6 + 0 + 10294.3)
=22516.9

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Piramal Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1647.4/264982.498
=0.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma EBIT Related Terms

Piramal Pharma EBIT Historical Data

* Premium members only.

The historical data trend for Piramal Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma EBIT Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial 6,737.60 2,175.60 6,262.40 8,362.30 1,647.40

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,764.80 71.30 362.40 -46.20 1,259.90

NSE:PPLPHARMA vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Piramal Pharma EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's EV-to-EBIT falls into.


NSE:PPLPHARMA
53GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Piramal Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,647 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹1,647 Mil mean?
Piramal Pharma (NSE:PPLPHARMA) has a EBIT of ₹1,647 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Piramal Pharma.
Is Piramal Pharma's EBIT too high?
Piramal Pharma's current EBIT is ₹1,647 Mil. Overall, Piramal Pharma has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's EBIT compare to ZTS and UTHR?
Piramal Pharma's EBIT of ₹1,647 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Piramal Pharma. Piramal Pharma's current EBIT is ₹1,647 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹175.28, compared to a current price of ₹167.69 — trading 4.3% below its estimated fair value. The current EBIT is ₹1,647 Mil. Piramal Pharma's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current EBIT is ₹1,647 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be undervalued. The current stock price of ₹167.69 is trading 4.3% below its estimated GF Value™ of ₹175.28. GuruFocus considers Piramal Pharma to be Fairly Valued.

Key valuation signals for NSE:PPLPHARMA:

  • EBIT: ₹1,647 Mil
  • GF Value™: ₹175.28 vs. price of ₹167.69 (4.3% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
53GF Score

Get the complete analysis for NSE:PPLPHARMA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹167.69
Price
₹175.28
GF Value